JMP Securities Lowers Athira Pharma (NASDAQ:ATHA) to Market Perform

JMP Securities lowered shares of Athira Pharma (NASDAQ:ATHA) from an outperform rating to a market perform rating in a research note published on Wednesday, MarketBeat reports.

Separately, Rodman & Renshaw began coverage on shares of Athira Pharma in a research report on Monday, August 19th. They set a buy rating and a $22.00 price objective for the company.

Athira Pharma Stock Performance

Shares of NASDAQ:ATHA opened at $0.61 on Wednesday. The stock’s 50-day simple moving average is $3.05 and its two-hundred day simple moving average is $2.78. The stock has a market capitalization of $23.40 million, a price-to-earnings ratio of -0.20 and a beta of 2.90. Athira Pharma has a 52-week low of $0.60 and a 52-week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. As a group, equities analysts forecast that Athira Pharma will post -2.56 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Kelly A. Romano bought 27,400 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were bought at an average price of $2.42 per share, for a total transaction of $66,308.00. Following the purchase, the director now owns 80,715 shares in the company, valued at $195,330.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Athira Pharma news, Director Kelly A. Romano acquired 15,000 shares of the company’s stock in a transaction dated Friday, June 21st. The stock was purchased at an average price of $2.26 per share, with a total value of $33,900.00. Following the completion of the purchase, the director now directly owns 53,315 shares in the company, valued at approximately $120,491.90. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kelly A. Romano bought 27,400 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were acquired at an average price of $2.42 per share, with a total value of $66,308.00. Following the transaction, the director now directly owns 80,715 shares of the company’s stock, valued at approximately $195,330.30. The disclosure for this purchase can be found here. Insiders own 19.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC bought a new stake in shares of Athira Pharma during the fourth quarter valued at approximately $32,000. Forefront Analytics LLC increased its holdings in Athira Pharma by 43.0% in the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after acquiring an additional 8,955 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Athira Pharma by 12.6% in the 4th quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock worth $13,129,000 after purchasing an additional 605,686 shares in the last quarter. Mirador Capital Partners LP bought a new position in shares of Athira Pharma during the 1st quarter valued at about $57,000. Finally, Acadian Asset Management LLC grew its position in shares of Athira Pharma by 281.5% during the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company’s stock valued at $1,505,000 after purchasing an additional 405,793 shares in the last quarter. 57.12% of the stock is currently owned by institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.